Cancer biotech Karyopharm Therapeutics sets terms for $85 million IPO

By
A A A

Karyopharm Therapeutics, a clinical-stage biotech developing treatments for cancer and other major diseases, announced terms for its IPO on Monday. The Natick, MA-based company plans to raise $85 million by offering 5.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Karyopharm Therapeutics would command a market value of $414 million.

Karyopharm Therapeutics, which was founded in 2008, plans to list on the NASDAQ under the symbol KPTI. Karyopharm Therapeutics initially filed confidentially on September 5, 2013. BofA Merrill Lynch and Leerink Swann are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: KPTI

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

74,282,785
  • $10.84 ▲ 11.64%
60,794,128
  • $17.12 ▲ 0.71%
55,628,662
  • $35.59 ▼ 1.00%
55,306,290
  • $116.47 ▲ 0.14%
55,118,241
  • $39.75 ▼ 0.43%
53,597,648
  • $9.41 ▲ 8.29%
41,889,990
  • $47.98 ▼ 1.48%
35,692,375
  • $97.34 ▼ 0.57%
As of 11/21/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com